Benzinga · Sep 11, 2026
XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know
XORTX Therapeutics shares rose 16.11% after hours after the biotech announced a key manufacturing milestone for its lead gout program.
XR
NASDAQ · XRTX
XORTX Therapeutics Inc.
Healthcare · Biotechnology
$2.33
Down-$0.26 (-11.16%)
Updated Sep 14, 2026, 10:47 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.34M
- P/E ratio
- -1.24
- Dividend yield
- 0.00%
- 52-week range
- $1.73 – $7.05
- Volume
- 1.92M
- Avg. volume
- 1.97M
Price performance
XRTX price history
1M range · 19 trading sessions · Daily adjusted prices
XRTX closed at $2.33 after 19 trading sessions, up 13.11% for the selected period.
- Last close
- $2.33
- Period change
- +13.11%
- Period low
- $2.00
- Period high
- $2.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.41 | $2.45 | $2.17 | $2.33 | 1.92M |
| Sep 10, 2026 | $2.4499 | $2.45 | $2.11 | $2.11 | 1.53M |
| Sep 9, 2026 | $2.26 | $2.31 | $2.15 | $2.158 | 14.89K |
| Sep 8, 2026 | $2.1937 | $2.38 | $2.1937 | $2.28 | 9.97K |
| Sep 4, 2026 | $2.285 | $2.45 | $2.23 | $2.31 | 14.28K |
| Sep 3, 2026 | $2.38 | $2.38 | $2.13 | $2.15 | 2.91K |
| Sep 2, 2026 | $2.18 | $2.48 | $2.11 | $2.48 | 5.82K |
| Sep 1, 2026 | $2.32 | $2.32 | $2.125 | $2.16 | 14.44K |
| Aug 31, 2026 | $2.18 | $2.34 | $2.18 | $2.32 | 5.22K |
| Aug 28, 2026 | $2.35 | $2.4374 | $2.30 | $2.338 | 24.23K |
| Aug 27, 2026 | $2.27 | $2.64 | $2.25 | $2.44 | 32.63K |
| Aug 26, 2026 | $2.27 | $2.3774 | $2.16 | $2.218 | 1.63K |
| Aug 25, 2026 | $1.89 | $2.39 | $1.88 | $2.26 | 41.91K |
| Aug 24, 2026 | $2.00 | $2.00 | $1.875 | $2.00 | 1.1K |
| Aug 21, 2026 | $2.0326 | $2.04 | $2.0326 | $2.04 | 1.69K |
| Aug 20, 2026 | $2.02 | $2.02 | $2.02 | $2.02 | 659 |
| Aug 19, 2026 | $2.06 | $2.06 | $2.00 | $2.00 | 4.24K |
| Aug 18, 2026 | $2.06 | $2.07 | $2.04 | $2.047 | 7.6K |
| Aug 17, 2026 | $2.08 | $2.33 | $2.02 | $2.06 | 10.07K |
Latest XRTX news
The latest Smart Investors Daily articles mentioning XRTX.
Stock researchCompany · Overview
XRTX research
Overview
Company profile and research snapshot.
Company profile
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 8, 2023 | ALLIANCE GLOBAL PARTNERS | Buy | — |
| May 7, 2023 | ALLIANCE GLOBAL PARTNERS | Buy | — |
| Apr 10, 2023 | ALLIANCE GLOBAL PARTNERS | Buy | — |
| Apr 22, 2022 | Alliance Global Partbers | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 10, 2026
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the launch of production of drug material and tablet manufacturing to support t
Benzinga · Sep 10, 2026
XORTX Therapeutics Starts Production Of Drug, Tablet Manufacturing For Its XRx-026 Trial To Treat Gout
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease,
Yahoo · Sep 8, 2026
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture Exchange, XORTX has re-engaged IR Agency LLC pursuant to a consulting agreement providing for investor relations and marketing services on substantially the same terms previously disclosed by the Company in its news releases dated May 19, 2026 and August 28, 2026. About XORTX Therapeutics
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
